Two new cancer medications have been approved for use in Saskatchewan.
The provincial government announced the expansion of the Saskatchewan Cancer Agency’s oncology drug formulary in a new release this week, adding the drugs Capivasertib and Relugolix — which are used to treat breast and prostate cancer — while also approving 13 new uses for drugs that are already being used in the province.
The new drugs will be available to patients later this spring, the Saskatchewan Ministry of Health said in the statement, and will benefit more than 450 residents of the province who are going through cancer treatment.